Understanding the BIOR Stock Situation: The Brutal Truth for Investors

If you are searching for "bior stock" updates, checking its latest price, or trying to find out why your broker changed the ticker symbol to "BIORQ," you are likely met with a wall of confusing charts, outdated algorithmic forecasts, and generic financial summaries.

The blunt reality is that Biora Therapeutics, Inc. (formerly trading under the Nasdaq ticker BIOR) is no longer a publicly traded operating company. Following a severe financial crisis, a delisting from the Nasdaq exchange, a Chapter 11 bankruptcy filing in December 2024, and a subsequent Section 363 asset sale in early 2025, the company's operational assets and intellectual property were sold to its secured lenders. Biora Therapeutics emerged as a privately held company in late March 2025, while the old public investment vehicle—represented by BIOR stock—was cancelled and converted into a Chapter 7 liquidation shell (BIORQ) with absolutely zero residual value for common retail shareholders.

This comprehensive guide will detail the rise and fall of Biora Therapeutics, analyze the revolutionary "smart pill" drug-delivery technology that drew retail investors to the stock, map out the timeline of the bankruptcy and asset sale, explain the current status of BIORQ, and provide key lessons that every biotech investor should take away from this high-risk penny stock collapse.

The Evolution of Biora Therapeutics: Diagnostic Roots and "Smart Pill" Tech

To understand the collapse of BIOR stock, it is first necessary to examine what the company did and why it initially generated so much market enthusiasm.

Biora Therapeutics did not start as an early-stage drug delivery developer. The company originally operated under the name Progenity, Inc. (and traded under the Nasdaq ticker PROG). Founded in 2010 and headquartered in San Diego, California, Progenity was primarily a molecular diagnostics provider. Its core products included the Preparent Carrier Test, the Innatal Prenatal Screen, and the Riscover Hereditary Cancer Test.

While diagnostic testing is highly valuable for patients, it is an incredibly brutal industry for micro-cap companies. Progenity faced mounting operational costs, intense competition from larger diagnostic giants, complex regulatory hurdles, and persistent battles with insurance providers over medical billing reimbursements. Realizing that the diagnostic business model was unsustainable, management initiated a massive strategic pivot.

In June 2021, the company began winding down its laboratory operations, laying off staff, and looking to monetize its non-core assets. In April 2022, Progenity officially rebranded as Biora Therapeutics, Inc., changing its ticker symbol from PROG to BIOR. This was not just a name change; it was a total repositioning of the company as an early-clinical-stage biotechnology firm focused on smart-pill therapeutic delivery platforms.

Biora developed two main ingestible drug-device combination platforms designed to revolutionize how biotherapeutics are delivered:

1. The NaviCap™ Targeted Oral Delivery Platform: Designed specifically for the treatment of inflammatory bowel disease (IBD), such as ulcerative colitis. Standard oral medications for IBD must pass through the stomach and small intestine, where they are absorbed systemically. This often leads to severe systemic side effects while leaving very little active medicine to treat the inflamed colon tissue. The NaviCap platform resolved this by using a swallowable "smart pill" equipped with Biora's proprietary GITrac™ localization technology. An internal optical sensor and localization algorithm detected changes in reflected light to identify when the device transitioned from the ileum to the colon. Once in the colon, the device released a liquid formulation of the therapeutic directly onto the diseased mucosa. Biora's leading clinical drug candidate using this platform was BT-600, which delivered a liquid formulation of tofacitinib (a JAK inhibitor).

2. The BioJet™ Oral Biotherapeutic Delivery Platform: A swallowable, needle-free autoinjector designed to replace painful injections for large macromolecules (proteins, peptides, and nucleic acids). Standard biotherapeutics cannot be taken orally as normal pills because digestive enzymes in the stomach destroy them before they can reach the bloodstream. The BioJet device bypassed this hurdle by autonomously delivering a liquid drug formulation directly into the submucosa of the small intestine using a precise, needle-free liquid jet injection.

In clinical trials, the technology showed immense promise. On July 1, 2024, Biora announced positive topline results from its Phase 1 clinical trial of BT-600 in healthy volunteers. The trial demonstrated that BT-600 achieved its pharmacokinetic goals: systemic drug exposure was significantly lower (one-quarter to one-third of standard oral tablets), while biopsies confirmed high drug concentration throughout the entire colon, including the distal portions.

Yet, while the science of localized drug delivery was making massive strides, Biora's capital structure was ticking toward a catastrophic collapse.

The Financial Downward Spiral: Dilution, Debt, and Reverse Splits

Early-stage biotech companies are notoriously cash-intensive. They must fund multi-million dollar clinical trials, pay specialized medical researchers, and maintain state-of-the-art facilities for years before obtaining FDA approval or securing commercial partnerships. Because Biora had shut down its diagnostic lab operations, it had virtually zero recurring revenue.

To survive, Biora had to continuously tap the public capital markets, creating a continuous cycle of dilution. Every time Biora executed a direct stock offering, it issued millions of new shares, which systematically diluted the value of existing holdings.

As the stock price consistently fell due to dilution and high cash burn, Biora ran into a major regulatory obstacle: the Nasdaq’s minimum bid price rule, which requires listed companies to maintain a stock price of at least $1.00. To artificially inflate its share price and avoid immediate delisting, Biora executed two massive reverse stock splits in less than two years:

• January 3, 2023: A 1-for-25 (0.04:1) reverse stock split.
• October 18, 2024: A 1-for-10 (0.1:1) reverse stock split.

While a reverse stock split temporarily raises the share price by consolidating the number of outstanding shares, it does absolutely nothing to change the underlying financial health of the business. In Biora's case, the reverse splits merely cleared the way for further dilution. Shortly after the October 2024 split, Biora announced a $3 million registered direct offering to secure emergency short-term cash.

Compounding this dilution was a heavy debt load. Biora carried more than $71 million in funded debt, much of it secured by the company's highly valuable intellectual property—namely, the BioJet and NaviCap platforms. When a pre-revenue company carries millions of dollars in secured debt, its common stock is in a highly precarious position. If the company cannot refinance its debt or raise enough capital to pay its interest, the secured lenders hold all the cards.

The Fall: Bankruptcy, 363 Asset Sale, and Privatization Timeline

By the end of 2024, Biora's cash runway had evaporated. With only about $1 million in cash remaining against over $71 million in debt, the company had reached its breaking point.

The final chapters of the public BIOR stock played out in rapid succession:

• December 10, 2024: With its market capitalization in freefall and facing severe liquidity constraints, Biora Therapeutics was officially delisted from the Nasdaq Global Market.
• December 27, 2024: Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the District of Delaware (Case No. 24-12849).
• The Section 363 Sale Plan: Rather than proposing a traditional reorganization plan to pay back creditors over time while keeping the public stock active, Biora's Chapter 11 filing was specifically designed to execute an expedited asset sale under Section 363 of the Bankruptcy Code. To keep the lights on during this process, Biora's primary secured lenders—including Davidson Kempner Capital Management LP, Context Capital Management LLC, and Highbridge Capital Management LLC—provided a debtor-in-possession (DIP) financing facility of up to $10.25 million in new money.
• The Stalking Horse Credit Bid: In exchange for this financing, the lender group acted as the "stalking horse" bidder. Because they were secured creditors, they were permitted to "credit-bid" the debt they were already owed to purchase the assets. In other words, they acquired Biora's revolutionary technology by wiping out the debt Biora owed them, rather than paying cash.
• February 27, 2025: The Delaware Bankruptcy Court formally approved the asset sale to the secured lender group.
• March 7, 2025: The Section 363 sale officially closed. Substantially all of Biora's intellectual property, laboratory equipment, clinical trial data, and ongoing operations were transferred to a new private corporate entity controlled by Davidson Kempner, Context Capital, and Highbridge.
• March 31, 2025: Biora Therapeutics announced the successful completion of its restructuring. It emerged as a leaner, privately held, well-capitalized company focused on progressing the BioJet and NaviCap platforms under its new private ownership.
• The Complete Equity Wipeout: Crucially, as part of the Plan of Reorganization, Biora's existing public common shares (BIOR) were officially cancelled. Public shareholders did not receive any shares in the newly structured private company, nor did they receive any cash payout.
• May 27, 2025: With its operational assets sold and its public shares cancelled, the defunct public shell of the company was converted from Chapter 11 to a Chapter 7 liquidation. Alfred T. Giuliano was appointed as the Chapter 7 trustee to reconcile any remaining claims and wind down the empty public entity.

What Happened to BIOR/BIORQ Shareholders?

For retail investors who purchased BIOR stock, the outcome is unfortunate but final.

When a company's common stock is cancelled under a bankruptcy plan, those shares are legally extinguished. They no longer represent any claim on the company's assets, intellectual property, or future revenues.

If you log into your brokerage account and see "BIORQ" in your portfolio, you may wonder why the shares still exist and occasionally tick up or down by fractions of a cent on the OTC Expert Market.

This residual trading is common with bankrupt public shells. Speculative day traders, automated market makers, and "shell hunters" trade these bankrupt tickers (which append a "Q" to signify bankruptcy) for fractions of a cent. They speculate on the microscopic possibility of a reverse merger or simply trade the high volatility of a stock with virtually zero liquidity.

However, for a retail investor, this trading is an illusion. The underlying operational business—the Biora Therapeutics developing the BioJet smart pill—is now a private company. The shares of BIORQ you hold have no relation to that private business. They are simply an empty corporate skin being liquidated under Chapter 7.

What should you do with your shares?

1. Understand They Are Worthless: You cannot sell them on standard major exchanges, and many retail brokerages have placed these shares under "position close only" (PCO) restrictions, meaning you can only hold or liquidate them for pennies, but you cannot buy more.
2. Consult a CPA for a Worthless Stock Tax Deduction: In many jurisdictions, including the United States, when a stock is officially cancelled or declared worthless via bankruptcy, you can write off the loss on your taxes. A certified public accountant can help you claim a worthless security deduction under Section 165(g) of the Internal Revenue Code, allowing you to use this loss to offset other capital gains or write off up to $3,000 of ordinary income.

Red Flags to Watch for in Biotech Investing

The story of Biora Therapeutics is a painful reminder of the unique risks associated with early-stage biotech stocks. While it is easy to get swept up in the exciting scientific possibilities of "smart pills" and "needle-free autoinjectors," investors must remember that a great scientific concept does not automatically translate into a great stock.

If you want to protect your capital and avoid the next BIOR-style wipeout, always look for these critical red flags when analyzing clinical-stage biotech stocks:

1. Sequential Reverse Stock Splits

A reverse split is a massive warning sign of underlying structural weakness. When a company performs a reverse split to keep its stock price above $1.00, it is usually because organic demand for the stock is non-existent. If a company performs multiple reverse stock splits (such as Biora's splits in 2023 and 2024), it is a screaming red flag that the stock is in a death spiral.

2. High Cash Burn vs. Insufficient Cash Runway

Always read the company's quarterly financial reports (Form 10-Q). Calculate the "cash runway" by dividing the total cash and cash equivalents on the balance sheet by the company's quarterly net loss (cash burn). If a pre-revenue biotech has less than 12 months of cash runway and is actively running clinical trials, it is highly likely that they will execute a massive dilutive stock offering, issue predatory debt, or face restructuring.

3. Secured Debt in Pre-Revenue Companies

Debt is incredibly dangerous for early-stage biotechs. If a company issues debt that is secured by its patent portfolio and intellectual property, the common stockholders are taking on extreme risk. If things go wrong, the secured lenders will simply seize the intellectual property through a bankruptcy court-approved asset sale (as happened with Biora), leaving common shareholders with absolutely nothing.

4. Continuous Pivot and Legacy Liabilities

Be wary of companies that undergo massive pivots from one industry to another (such as Progenity shifting from diagnostic tests to early-stage drug delivery). These pivots often mean the company is carrying massive legacy liabilities, unresolved legal claims, or debt from its previous business model, making it incredibly difficult to achieve financial stability.

Frequently Asked Questions

Is BIOR stock still trading?

No, BIOR stock is no longer trading on the Nasdaq Global Market. It was delisted in December 2024. The bankrupt public shell currently trades under the ticker symbol BIORQ on the over-the-counter (OTC) Expert Market, where it has practically zero value and is subject to strict trading restrictions.

Can I buy shares of the new Biora Therapeutics?

No. Biora Therapeutics successfully completed its court-supervised restructuring in March 2025 and emerged as a privately held company. Its ownership has transitioned completely to its secured lenders, including Davidson Kempner Capital Management LP, Context Capital Management LLC, and Highbridge Capital Management LLC. There are no public shares available for purchase.

Why did Biora Therapeutics file for Chapter 11 bankruptcy?

Biora faced severe financial distress due to high clinical-stage cash burn, millions of dollars in legacy liabilities from its Progenity diagnostic operations, and over $71 million in funded debt. With only $1 million in cash remaining by late 2024, the company was forced to file for Chapter 11 bankruptcy to execute an expedited Section 363 asset sale.

Will old BIOR shareholders get anything from the private company?

No. Under the court-approved Plan of Reorganization, all existing public common stock of Biora Therapeutics was cancelled and wiped out. Old BIOR/BIORQ shareholders do not have any ownership stake or claims in the newly restructured private company.

Can I write off my losses on BIOR/BIORQ stock on my taxes?

Yes. In most cases, you can claim a capital loss for tax purposes once your broker or the court declares the security worthless. You should consult a tax professional or CPA to file a worthless security deduction to help offset your capital gains or ordinary income.

Conclusion: A Valuable Lesson in Biotech Risk

Biora Therapeutics is a classic example of a company with brilliant scientific concepts but an unsustainable capital structure. Its innovative smart-pill platforms, BioJet and NaviCap, represented a genuine technological leap forward for targeted drug delivery.

Unfortunately, the financial reality of high cash burn, constant dilution, back-to-back reverse splits, and massive secured debt ultimately doomed the public stock. While the technology itself may live on in the private sector under the ownership of its former lenders, retail BIOR stock investors were completely wiped out.

For retail investors, the collapse of BIOR stock serves as an invaluable warning: always prioritize balance sheet health, cash runway, and capital structure over scientific promise. In the volatile world of clinical biotech, a revolutionary drug pipeline is only as strong as the cash reserves backing it.